Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early proactive therapeutic drug monitoring of infliximab in pediatric inflammatory bowel disease
2021-003220-32Phase 4Active
- Sponsor
- IRCCS Burlo Garofolo
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in inflammatory bowel disease (IBD) (2 arms), sponsored by IRCCS Burlo Garofolo. Primary endpoint: Primary composite endpoint. Started Oct 2021; status: active.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2021-003220-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003220-32.